The stock closed at €79.00, up 3.54% from the previous session which had settled at €76.30. This increase occurred in a downward trending Parisian market, with the CAC 40 falling by 0.23%. Trading volumes remained moderate, at 0.09% of the capital, indicating a bullish movement without massive flows. Over the week, the stock has shown a gain of 11.11%, bringing its three-month performance to over 1,050% and 829.4% over one year, starkly contrasting with the CAC 40's 6.91% over the same period. This momentum follows the presentation on October 6 of positive phase 3 results for obezafimod in the treatment of ulcerative colitis at the UEG congress in Berlin. The 50 mg dose candidate demonstrated clinically significant improvements, with no new tolerance signals. Furthermore, JP Morgan Chase reported crossing the 5% voting rights threshold of Abivax on October 6, holding 5.65% of the capital and 5.12% of the voting rights on that date.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
From a technical perspective, the stock has clearly broken through its technical resistance at €76.50, signaling a continuation of the recent bullish momentum. The RSI, which measures the strength of a movement, stands at 67, approaching the overbought zone beyond 70, which may indicate strong momentum but also a risk of temporary fatigue. The stock is significantly above its 50-day moving average at €67.57 and its 200-day average at €23.14, reflecting a marked appreciation over the year. The MACD, a moving average convergence-divergence indicator, shows a line at 1.57 above its signal at 1.25, with a positive histogram of 0.32, confirming an active bullish trend. The price is also above the upper Bollinger band set at €75.33, suggesting an extension of short-term volatility. With a beta of 2.00, Abivax exhibits double sensitivity to CAC 40 movements, amplifying both upward and downward market trends.
Trésorerie et équivalents de trésorerie de 589,7 millions d'euros au 30/09/2025 ; perte nette de 254,1 millions d'euros sur les neuf mois ; produit net d'ADS d'environ 700,3 millions de dollars (?597,2 M€) en juillet 2025 ; position financière nette de 543,3 millions d'euros ; autonomie financière attendue jusqu'au T4 2027. Hausse significative des dépenses R&D et des charges G&A.
Risks mentioned
Risques inhérents à la recherche et au développement clinique
Risque lié aux décisions des autorités réglementaires (FDA, EMA)
Risque de disponibilité insuffisante de fonds pour couvrir les dépenses d'exploitation futures
Obstacles potentiels au développement clinique et pharmaceutique (données précliniques, CMC, toxicologie, etc.)
Opportunities identified
Avancement des essais de phase 3 d'Obefazimod en rectocolite hémorragique
Présentations 'late-breaking' et résultats favorables communiqués lors de congrès scientifiques
Produit net élevé de l'offre d'ADS prolongeant l'autonomie financière jusqu'au T4 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
